A Phase 2 Study of BMS-986504 in People With Non-Small Cell Lung Cancer

Full Title

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies

Purpose

Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.

BMS-986504 blocks PRMT5, an enzyme that plays a role in cancer cell growth. BMS-986504 blocks processes that promote growth in MTAP-deleted cancer cells, while sparing cells without cancer. It is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.

Protocol
25-200
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Kathryn C. Arbour
Co-Investigators
Helena A. Yu
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06855771
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description